Recurrent mutations refine prognosis in chronic lymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Chronic lymphocytic leukemia (CLL) is a heterogeneous B-cell malignancy.
• Identifying recurrent genetic mutations is crucial for understanding CLL pathogenesis and prognosis.
• Previous studies have identified several key genes, but comprehensive screening in large patient cohorts is needed.

Purpose of the Study:

• To screen a large cohort of CLL patients for mutations in key genes including NOTCH1, SF3B1, TP53, MYD88, and BIRC3.
• To correlate mutation status with clinical and biological features of CLL.
• To assess the prognostic impact of these mutations on treatment initiation and outcomes.

Main Methods:

• Screening of 3490 CLL patients for mutations in NOTCH1, SF3B1, TP53, MYD88, and BIRC3 genes.
• Analysis of mutation frequencies and their association with clinical parameters like IGHV mutational status, cytogenetic abnormalities, and disease stage.
• Correlation of mutation status with time-to-first-treatment in treatment-naive patients.

Main Results:

• BIRC3 mutations associated with unmutated IGHV (U-CLL), del(11q), and trisomy 12; MYD88 mutations found exclusively in M-CLL.
• NOTCH1, SF3B1, and TP53 mutations were enriched in aggressive cases.
• SF3B1 and TP53 mutations, along with del(11q) and U-CLL, independently predicted shorter time-to-first-treatment, with TP53ab and SF3B1 mutations showing adverse impact even in U-CLL.

Conclusions:

• Recurrent mutations in SF3B1 and TP53 have significant adverse prognostic implications in CLL.
• The prognostic impact of SF3B1 and TP53 mutations is independent of IGHV mutational status.
• Standardization and harmonization of mutation detection methods are essential for clinical application.